Type-2 diabetes (T2D) patients with body mass index (BMI) below 35 kg/m2 carry lower remission rates than severely obese T2D individuals submitted to “standard limb lengths” Roux-en-Y gastric bypass (RYGB). Mild-obese patients appear to have more severe forms of T2D, where the mechanisms of glycemic control after a standard-RYGB may be insufficient. The elongation of the biliopancreatic limb may lead to greater stimulation of the distal intestine, alterations in bile acids and intestinal microbiota, among other mechanisms, leading to better metabolic outcomes. The aim of this study is to evaluate the safety and efficacy of the RYGB with a biliopancreatic limb of 200 cm in the control of T2D in patients with BMI 30–35 kg/m2.
From January 2011 to May 2015, 102 T2D patients with BMI from 30 to 34.9 kg/m2 underwent laparoscopic RYGB with the biliopancreatic-limb of 200 cm and the alimentary-limb of 50 cm.
There were no deaths or reoperations. The mean follow-up was 28.1 months. The mean BMI dropped from 32.5 to 25.1 kg/m2, while the mean fasting glucose decreased from 182.9 to 89.8 mg/dl and the mean glycated hemoglobin (HbA1c) went from 8.7 to 5.2%. During follow-up, 92.2% had their T2D under complete control (HbA1c < 6%, no anti-diabetic medications), while 7.8% were under partial control. Control of hypertension and dyslipidemia were 89.4 and 85.5%, respectively. No patient developed hypoalbuminemia, and there were mild micronutrient deficiencies.
RYGB with long-biliopancreatic and short-alimentary limbs is safe and seems effective in achieving complete control of T2D in patients with BMIs between 30 and 35 kg/m2.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Angrisani L, Santonicola A, Iovino P, et al. Bariatric surgery worldwide 2013. Obes Surg. 2015;25(10):1822–32.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122(3):248–56.
Hsu CC, Almulaifi A, Chen JC, et al. Effect of bariatric surgery vs medical treatment on type 2 diabetes in patients with body mass index lower than 35: five-year outcomes. JAMA Surg. 2015;150(12):1117–24.
Xu L, Yin J, Mikami DJ, et al. Effectiveness of laparoscopic roux-en-Y gastric by-pass on obese class I type 2 diabetes mellitus patients. Surg Obes Relat Dis. 2015;11(6):1220–6.
Scopinaro N, Adami GF, Papadia FS, et al. Effects of gastric bypass on type 2 diabetes in patients with BMI 30 to 35. Obes Surg. 2014;24(7):1036–43.
Lee WJ, Chong K, Chen CY, et al. Diabetes remission and insulin secretion after gastric by-pass in patients with body mass index <35 kg/m2. Obes Surg. 2011;21(7):889–95.
Boza C, Valderas P, Daroch DA, et al. Metabolic surgery: roux-en-Y gastric bypass and variables associated with diabetes remission in patients with BMI <35. Obes Surg. 2014;24(8):1391–7.
Cohen RV, Pinheiro JC, Schiavon CA, et al. Effects of gastric bypass surgery in patients with type 2 diabetes and only mild obesity. Diabetes Care. 2012;35(7):1420–8.
Madan AK, Tichansky DS, Phillips JC. Does pouch size matter? Obes Surg. 2007;17(3):317–20.
Odstrcil EA, Martinez JG, Santa Ana CA, et al. The contribution of malabsorption to the reduction in net energy absorption after long-limb roux-en-Y gastric by-pass. Am J Clin Nutr. 2010;92(4):704–13.
Saeidi N, Meoli L, Nestoridi E, et al. Reprogramming of intestinal glucose metabolism and glycemic control in rats after gastric by-pass. Science. 2013;341(6144):406–10.
Holst JJ, Madsbad S. Mechanisms of surgical control of type 2 diabetes: GLP-1 is key factor. Surg Obes Relat Dis. 2016;12(6):1236–42.
Trabelsi MS, Lestavel S, Staels B, et al. Intestinal bile acid receptors are key regulators of glucose homeostasis. Proc Nutr Soc. 2016;16:1–11. [Epub ahead of print]
Kaska L, Sledzinski T, Chomiczewska A, et al. Improved glucose metabolism following bariatric surgery is associated with increased circulating bile acid concentrations and remodeling of the gut microbiome. World J Gastroenterol. 2016;22(39):8698–719.
Rajagopalan H, Cherrington AD, Thompson CC, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes: 6-month interim analysis from the first-in-human proof-of-concept study. Diabetes Care. 2016;39(12):2254–61.
Müller MK, Räder S, Wildi S, et al. Long-term follow-up of proximal versus distal laparoscopic gastric by-pass for morbid obesity. Br J Surg. 2008;95(11):1375–9.
Miyachi T, Nagao M, Shibata C, et al. Biliopancreatic limb plays an important role in metabolic improvement after duodenal-jejunal by-pass in a rat model of diabetes. Surgery. 2016;159(5):1360–71.
Chamberlain JJ, Rhinehart AS, Shaefer Jr CF, et al. Diagnosis and management of diabetes: synopsis of the 2016 American Diabetes Association Standards of Medical Care in Diabetes. Ann Intern Med. 2016;164(8):542–52.
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42(6):1206–52.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2014; 63 (25 Pt B): 2889-2934
Kaska L, Kobiela J, Proczko M, et al. Does the length of the biliary limb influence medium-term laboratory remission of type 2 diabetes mellitus after roux-em-Y gastric by-pass in morbidly obese patients? Wideochir Inne Tech Maloinwazyjne. 2014;9(1):31–9.
Pinheiro JS, Schiavon CA, Pereira PB, et al. Long-long limb roux-en-Y gastric by-pass is more efficacious in treatment of type 2 diabetes and lipid disorders in super-obese patients. Surg Obes Relat Dis. 2008;4(4):521–5.
Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric surgery versus intensive medical therapy for diabetes—5-year outcomes. N Engl J Med. 2017;376(7):641–51.
Cummings DE. Endocrine mechanisms mediating remission of diabetes after gastric bypass surgery. Int J Obes. 2009;33(Suppl 1):S33–40.
Guedes TP, Martins S, Costa M, et al. Detailed characterization of incretin cell distribution along the human small intestine. Surg Obes Relat Dis. 2015;11(6):1323–31.
Nergård BJ, Lindqvist A, Gislason HG, et al. Mucosal glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide cell numbers in the super-obese human foregut after gastric bypass. Surg Obes Relat Dis. 2015;11(6):1237–46.
Salinari S, le Roux CW, Bertuzzi A, et al. Duodenal-jejunal bypass and jejunectomy improve insulin sensitivity in Goto-Kakizaki diabetic rats without changes in incretins or insulin secretion. Diabetes. 2014;63(3):1069–78.
Nergaard BJ, Leifsson BG, Hedenbro J, et al. Gastric bypass with long alimentary limb or long pancreato-biliary limb—long-term results on weight loss, resolution of co-morbidities and metabolic parameters. Obes Surg. 2014;24(10):1595–602.
Nora M, Guimarães M, Almeida R, et al. Metabolic laparoscopic gastric bypass for obese patients with type 2 diabetes. Obes Surg. 2011;21(11):1643–9.
Lanzarini E, Csendes A, Gutierrez L, et al. Type 2 diabetes mellitus patients with mild obesity: preliminary results of surgical treatment. Obes Surg. 2013;23(2):234–40.
Inabnet WB, Quinn T, Gagner M, et al. Laparoscopic roux-en-Y gastric bypass in patients with BMI <50: a prospective randomized trial comparing short and long limb lenghts. Obes Surg. 2005;15(1):51–7.
Kellum JM, Chikunguwo SM, Maher JW, et al. Long-term results of malabsorptive distal roux-en-Y gastric bypass in superobese patients. Surg Obes Relat Dis. 2011;7(2):189–93.
Risstad H, Svanevik M, Kristinsson JA, et al. Standard vs distal roux-en-Y gastric bypass in patients with body mass index 50 to 60: a double-blind. Randomized Clinical Trial JAMA Surg. 2016;151(12):1146–55.
Marceau P, Biron S, Hould FS, et al. Duodenal switch: long-term results. Obes Surg. 2007;17(11):1421–30.
Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery. 1996;119(3):261–8.
Maiz C, Alvarado J, Quezada N, et al. Bariatric surgery in 1119 patients with preoperative body mass index<35 (kg/m(2)): results at 1 year. Surg Obes Relat Dis. 2015;11(5):1127–32.
Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: a meta-analysis of clinical trials. Diabetes Obes Metab. 2013;15(8):737–49.
Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and lowering glycemia: results of a systematic meta-analysis and meta-regression. Am J Hypertens. 2014;27(1):130–9.
Dallinga-Thie GM, Nieuwdorp M. GLP-1, an important regulator of intestinal lipid metabolism. Arterioscler Thromb Vasc Biol. 2015;35(5):1048–9.
Schonewille M, de Boer JF, Groen AK. Bile salts in control of lipid metabolism. Curr Opin Lipidol. 2016;27(3):295–301.
There was no financial support for this study.
Conflict of Interest
The authors declare that they have no conflict of interest.
Obtained for every patient.
About this article
Cite this article
Murad, A.J., Cohen, R.V., de Godoy, E.P. et al. A Prospective Single-Arm Trial of Modified Long Biliopancreatic and Short Alimentary Limbs Roux-En-Y Gastric Bypass in Type 2 Diabetes Patients with Mild Obesity. OBES SURG 28, 599–605 (2018). https://doi.org/10.1007/s11695-017-2933-x
- Long biliopancreatic limb
- Roux-en-Y gastric bypass
- Metabolic surgery in mild obesity
- Type-2 diabetes